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Background: Patients with multiple colorectal adenomas are currently screened for germline mutations in two
genes, APC and MUTYH. APC-mutated patients present classic or attenuated familial adenomatous polyposis (FAP/
AFAP), while patients carrying biallelic MUTYH mutations exhibit MUTYH-associated polyposis (MAP). The spectrum
of mutations as well as the genotype-phenotype correlations in polyposis syndromes present clinical impact and
can be population specific, making important to obtain genetic and clinical data from different populations.
Methods: DNA sequencing of the complete coding region of the APC and MUTYH genes was performed in 23
unrelated Brazilian polyposis patients. In addition, mutation-negative patients were screened for large genomic
rearrangements by multiplex ligation-dependent probe amplification, array-comparative genomic hybridization, and
duplex quantitative PCR. Biallelic MUTYH mutations were confirmed by allele-specific PCR. Clinical data of the index
cases and their affected relatives were used to assess genotype–phenotype correlations.
Results: Pathogenic mutations were identified in 20 of the 23 probands (87%): 14 in the APC gene and six in the
MUTYH gene; six of them (30%) were described for the first time in this series. Genotype-phenotype correlations
revealed divergent results compared with those described in other studies, particularly regarding the extent of
polyposis and the occurrence of desmoid tumors in families with mutations before codon 1444 (6/8 families with
desmoid).
Conclusions: This first comprehensive investigation of the APC and MUTYH mutation spectrum in Brazilian
polyposis patients showed a high detection rate and identified novel pathogenic mutations. Notably, a significant
number of APC-positive families were not consistent with the predicted genotype-phenotype correlations from
other populations.
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Patients with multiple colorectal adenomas are screened
for germline mutations in two distinct genes, APC and
MUTYH. According to the polyp number and age of on-
set, the phenotype of APC-mutated patients can be clas-
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reproduction in any medium, provided the ormore than 100 polyps, early onset) or attenuated FAP
(AFAP: fewer than 100 polyps with later onset) [1-3].
MUTYH biallelic mutation carriers usually present 10 to
100 polyps and are categorized as having MUTYH-asso-
ciated polyposis (MAP) [4].
FAP/AFAP (OMIM #175100) is a dominantly inherited
colorectal cancer (CRC) predisposing syndrome [1,2]
caused by mutations in the tumor suppressor gene aden-
omatous polyposis coli (APC). The encoded APC pro-
tein controls β-catenin turnover in the Wnt pathway
[5,6]. Besides colonic polyposis and colorectal cancer,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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extracolonic features, including multiple osteomas, epi-
dermoid cysts, desmoid tumors, and congenital hyper-
trophy of the retinal pigment epithelium [2]. Over 1100
different pathogenic APC mutations have been reported
to date in the Leiden Open Variation Database (http://
www.lovd.nl/2.0/), the majority of them being nonsense
mutations or small insertions or deletions that lead to a
truncated protein. Mutations causing AFAP have been
reported to occur mainly in three regions of APC: at the
50 end (the first five exons), in the alternatively spliced re-
gion of exon 9, or at the 30 end (after codon 1580) [7-9].
MAP (OMIM #608456) is a recessively inherited syn-
drome caused by biallelic mutations in the mutY homolog
(MUTYH) gene that maps to chromosome 1p34.1 [4].
MUTYH encodes a DNA glycosylase that plays a key role
in the base excision repair pathway by removing mispaired
bases caused by the oxidation product 8-oxoG [4]. Nearly
300 different sequence variants have been identified in this
gene (LOVD Mutation Database), including about 80
pathogenic mutations distributed throughout the gene at
positions corresponding to different functional domains of
the encoded protein [10]. In contrast to APC pathogenic
variants, which mostly result in a truncated or absent pro-
tein, most MUTYH pathogenic variants are missense sub-
stitutions and only a minority are splice site or truncating
mutations [11].
With regard to clinical features, most MUTYH-mutated
patients present 10 to 100 colorectal adenomas, usually
with later onset compared with FAP patients [4,12,13].
MUTYH mutation carriers represent approximately 7.5%
of patients with more than 100 adenomas without an APC
mutation, 40% of all patients with 10–100 polyps, and
0.3–1.7% of patients with fewer than 10 polyps and early-
onset CRC with no family history [12,14-16]. Furthermore,
it has also been reported MAP patients having no polyps
at the time of CRC diagnosis [17,18].
Because of the observed overlap between the clini-
cal phenotype of FAP/AFAP and MAP syndromes, the
identification of the causative mutation has important
implications for family management, allowing effective
clinical surveillance and accurate genetic counseling.
Moreover, the spectrum of mutations and the genotype–
phenotype correlations may have clinical impact and can
be population-specific. Therefore, it is important to ob-
tain genetic and clinical data from FAP/AFAP and MAP
families in different populations.
The aim of this study was to conduct a comprehensive
molecular analysis to determine the spectrum of point mu-
tations and large genomic rearrangements (LGR) in the
APC and MUTYH genes in a series of 23 Brazilian polyp-
osis patients. This paper summarizes the mutation screen-
ing data and outlines the most cost-effective approach to
detect APC and MUTYH mutations in Brazilian polyposispatients. In addition, we discuss the genotype–phenotype
associations found in these families in the context of previ-
ously described data from the literature.
Methods
Patients
The study examined the Hereditary Colorectal Cancer
Registry of A. C. Camargo Hospital (São Paulo, Brazil)
[19], for families clinically suspected for FAP (> 100 co-
lorectal adenomas) or AFAP/MAP (10–100 colorectal
adenomas), enrolled between January 1998 and July 2011.
Between 2010 and 2011, the genetic test was offered to
forty registered unrelated polyposis families, from which
23 were available and willing to undergo genetic testing.
Index patients were interviewed after providing informed
consent and the family history was obtained through ver-
bal report and, whenever possible, confirmed with clinical
or pathological reports.
This study was performed in compliance with the Dec-
laration of Helsinki and was approved by the ethics com-
mittee of A. C. Camargo Hospital (approval number:
1169/08-B). Once a mutation was identified in the index
case, genetic counseling and molecular testing were of-
fered to relatives.
PCR and sequence analysis
Mutation screening was performed by capillary sequencing
of all coding exons of the APC [GenBank:NM_000038.5]
and MUTYH [GenBank:NM_001128425.1] genes, in-
cluding the intron–exon boundaries. Patients clinically
suspected for FAP (> 100 polyps) were first screened for
APC mutations, while patients with attenuated polyposis
(< 100 polyps) were first screened for MUTYH mutations.
Patients negative for the first screened gene were then
screened for the remaining one.
Genomic DNA was obtained from leukocytes using a
Puregene Genomic DNA Isolation Kit (Gentra Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions. PCR reactions used 25 ng of template and
500 nM of each primer in a final volume of 20 μl with
GoTaq Green Master Mix (Promega, Madison, WI, USA).
Approximately 200 ng of PCR-amplified fragments were
purified with ExoSAP-IT (USB Corporation, Cleveland,
OH, USA) and sequenced in both directions. Products
were analyzed using an ABI 3130xl DNA sequencer (Ap-
plied Biosystems, Foster City, CA, USA) and the resulting
sequences were aligned using CLCBio Genomics Work-
bench Software (Muehltal, Germany). The sequences of
primers used for these analyses are available upon request.
All mutations were confirmed in a second DNA sam-
ple. Mutations were recorded and referenced with re-
spect to the cDNA sequence, using the nomenclature
guidelines proposed by the Human Genome Sequence
Variation Society (www.hgvs.org/mutnomen).
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Allele-specific PCR [20] was performed for MUTYH mu-
tations to confirm the presence of two heterozygous
alleles (compound heterozygosity). Primers were designed
to be specific for the wild-type or mutated nucleotide of
one of the MUTYH mutations. Sequencing of allele-
specific PCR amplicons was performed to reveal the
haplotype phase of the second mutation. PCR conditions
and primers are available upon request.
LGR screening
Seven patients were selected for LGR screening using
multiplex ligation-dependent probe amplification (MLPA),
array-comparative genomic hybridization (aCGH), and
duplex quantitative PCR (qPCR): five negative for APC or
MUTYH point mutations, one with a novel APC missense
variant, and one with a monoallelic MUTYH mutation.
All experiments were performed in duplicate.
MLPA was performed using the SALSA P043-C1
APC Probemix kit (MRC Holland, Amsterdam, The
Netherlands) following the manufacturer’s protocol. PCR
products were analyzed using an ABI 3130xl DNA se-
quencer (Applied Biosystems - Foster City, CA, USA),
and gene dosage was calculated using Coffalyser V9.4
software (MRC Holland, Amsterdam, The Netherlands).
The aCGH platform used in this study was the
SurePrint G3 Human CGH Microarray Kit 4 × 180 k
(G4449A; Agilent Technologies, Santa Clara, CA, USA),
which has an average resolution of 18 kb, with 13 and
three probes located within APC and MUTYH, respect-
ively. Briefly, samples were labeled with Cy3- or Cy5-
dCTPs by random priming. Purification, hybridization,
and washing were performed as recommended by the
manufacturer. Data extraction was conducted using Fea-
ture Extraction software (Agilent Technologies - Santa
Clara, CA, USA). Genomic Workbench software (Agilent
Technologies - Santa Clara, CA, USA) was applied to
identify constitutive genomic imbalances using the statis-
tical algorithm ADM-2, with a sensitivity threshold of 6.7,
and a threshold log2 ratio of 0.4 for duplication and −0.4
for deletion.
Genomic alterations identified by MLPA and aCGH
were validated using the duplex qPCR method previ-
ously established by our group [21].
Variant analysis
Mutations in the APC or MUTYH genes were consid-
ered deleterious if they: a) were classified as pathogenic
in LOVD database; b) introduced a premature stop
codon in the protein sequence (nonsense or frameshift
mutation); c) occurred at donor or acceptor splice sites;
or d) were whole-exon deletions or duplications. To es-
tablish the pathogenicity of one novel missense variant,
web-based programs that predict the effect of an ami-no acid substitution were applied (SIFT, Polyphen, and
MutationTaster). In addition, the frequency of this vari-
ant was assessed in 95 healthy Brazilian individuals.
Clinical features and genotype-phenotype correlations
The following clinical and pathological data were
obtained from all families from the Hereditary Colorectal
Cancer Registry of A. C. Camargo Hospital [19]: num-
ber of affected individuals, age at diagnosis, number of
patients with extracolonic features, and primary sites of
extracolonic tumors. The extent of polyposis burden
(number of adenomas) was assessed for the index cases
through colonoscopy records and/or pathological report
from surgical specimens. For most family members this
information was unavailable. Patients and their families
were grouped according to the affected gene and the
index case polyposis burden into five categories: group 1,
APC-mutated families with fewer than 100 colorectal ad-
enomas (attenuated polyposis); group 2, APC-mutated
families with 100–1000 adenomas (intermediate polyp-
osis); group 3, APC-mutated families with more than
1000 adenomas (severe polyposis); group 4, MUTYH-
mutated families; and group 5, mutation-negative families.
Genotype–phenotype correlations in the three APC-
mutated groups were compared with those previously de-
scribed, as reviewed by Nieuwenhuis and Vasen (2007)
[22]. This review evaluated a large number of studies in
FAP patients and proposed a categorization of the pheno-
types according to the severity of the polyposis and the
associated site of the APC mutation.
Statistical evaluation was performed using the Stu-
dent’s t-test using Prism 5 software (GraphPad, San
Diego, CA, USA). Statistical significance was set at a
p-value < 0.05.
Results
Twenty-three Brazilian families with a clinical diagnosis
of classical or attenuated polyposis were included in this
study. The majority of the index cases (15) presented
an intermediate or severe FAP phenotype (> 100 polyps)
and 13 of them harbored an APC pathogenic mutation,
while one patient was mutation-negative and one had a
monoallelic MUTYH mutation. The remaining eight pa-
tients presented an attenuated polyposis burden (< 100
polyps), among whom five carried biallelic mutations in
the MUTYH gene, one carried a novel APC duplication
of exons 1–3, one presented a novel APC missense vari-
ant, and one was mutation-negative. Seven novel germline
mutations (six pathogenic and one variant of unknown
significance) were detected in this cohort, and two of
them have been recently published by our group [21,23].
The APC and MUTYH mutation spectrum, including in-
formation about previous reports of the detected muta-
tions, is summarized in Table 1.
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Fourteen pathogenic APC mutations were identified in
this series: three small duplications, five small deletions,
four nonsense mutations, one multiple exon duplication,
and one whole-gene deletion. Six of them were novel mu-
tations (Table 1). All patients presented distinct mutations,
except for two unrelated probands that presented the
hotspot mutation at codon 1309 (c.3927–3931delAAAGA;
p.Glu1309Aspfs*4).
One patient (ID13) presented a novel missense APC vari-
ant of unknown significance: c.5365G >C (p.Val1789Leu).
This patient was diagnosed with attenuated polyposis at
the age of 56 years, presenting around 20 polyps at the time
of clinical diagnosis. In silico studies using three differ-
ent functional prediction programs (Polyphen, SIFT and
MutationTaster), which all classified the p.Val1789Leu vari-
ant as having minimal or no effect on protein function,
with the following scores: 0 (Polyphen); 0.30 (SIFT); 0.87
(P: 0.99, MutationTaster). Because the proband was theTable 1 APC and MUTYH mutation spectrum in Brazilian poly
ID Gene Mutation
Mutation-positive patients w
02 APC del 5q21.3-q22.3 (chr5:107916475–113079330 Hg19)
04 APC c.856_859dupCATG (p.Glu287Alafs*2)
05 APC c.447dupC (p.Lys150Glnfs*18)
23 APC c.4097dupC (p.Gln1367Serfs*8)
01 APC c.904C > T (p.Arg302*)
03 APC c.4348C > T (p.Arg1450*)
06 APC c.3880-3881delCA (p.Gln1294Glyfs*6)
07 APC c.847C > T (p.Arg283*)
08 APC c.4099C > T (p.Gln1367*)
10 APC c.3050-3053delATGA (p.Asn1017Metfs*4)
11 APC c.3927-3931delAAAGA (p.Glu1309Aspfs*4)
14 APC c.4393-4394delAG (p.Ser1465Trpfs*3)
21 APC c.3927-3931delAAAGA (p.Glu1309Aspfs*4)
24 MUTYH c.[1187G > C];[=] (p.[Gln396Asp];[=])
Mutation-positive patients w
15 MUTYH c.[348 + 33_*64 + 146del4285insTA]; [348 + 33_*64 + 146del
13 APC c.5365G > C (p.Val1789Leu)c
17 APC Exon 1–3 duplication
16 MUTYH c.[536A > G]; [1147delC] (p.[Tyr179Cys]; [Ala385Profs*23])
18 MUTYH c.[389-1G > C]; [536A > G] (p.[Val130GlufsX98;p.(spl?)]; [Tyr17
19 MUTYH c.[721C > T]; [721C > T] (p.[Arg241Trp]; [Arg241Trp])
447 MUTYH c.[536A > G]; [1227-1228dup] (p.[Tyr179Cys]; [Glu410Glyfs*43
a The following databases were consulted: LOVD: http://www.lovd.nl/2.0/; dbSNP: h
http://www.1000genomes.org/; b Number of times reported at LOVD database; c Vaonly affected member of the family, it was not possible
to perform co-segregation analysis of the variant with the
disease within the family; nevertheless, this variant was not
detected in a control population of 95 healthy individuals.
In this series, two patients presented APC LGRs, identi-
fied by MLPA and/or aCGH and confirmed by gene dos-
age qPCR. Patient ID02 presented a 5.2-Mb deletion at
5q21.3–q22.3 that encompassed the entire APC gene and
19 additional genes, which have been previously published
by our group [21]. The second patient (ID17) presented a
duplication of APC exons 1–3 that was identified by
MLPA (Figure 1A) and validated by duplex qPCR [21]
(Figure 1B).
MUTYH mutations
Biallelic germline mutations in the MUTYH gene were
identified in five patients, among whom two were homo-
zygotes for the causative mutation and the remaining
three were compound heterozygotes for two distinctposis patients
Exon Type Ref.a reported N timesb
ith > 100 polyps
1-15 gene deletion Torrezan et al. [21] 1
8 duplication Current study 0
4 duplication Current study 0
15 duplication Current study 0
8 nonsense Mandl et al. [24] 22
15 nonsense Miyaki et al. [25] 40
15 deletion Miyaki et al. [25] 1
8 nonsense Mandl et al. [24] 49
15 nonsense Friedl and Aretz [26] 8
15 deletion Vandrovcová et al. [27] 2
15 deletion Miyoshi et al. [28] 304
15 deletion Miyoshi et al. [28] 40
15 deletion Miyoshi et al. [28] 304
13 missense Al-Tassan et al. [4] 532
ith < 100 polyps
4285insTA] 4-16 large deletion Torrezan et al. [23] 2
15 missense Current study 0
1-3 large duplication Current study 0
7;12 missense; Al-Tassan et al. [4] 532;
deletion Eliason et al. [29] 71
9Cys]) i4;7 splice site; Olschwang et al. [30] 2;
missense Al-Tassan et al. [4] 532
9 missense Fleischmann et al. [31] 11
]) 7;13 missense; Al-Tassan et al. [4]; 506;
duplication Baglioni et al. [32] 31
ttp://www.ncbi.nlm.nih.gov/projects/SNP/; and 1000 Genomes:
riant of unknown clinical significance.
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fied in one patient.
One patient (ID19) and her brother were homozygous
for the p.Arg241Trp missense mutation, because of a
consanguineous marriage between the parents. The sec-
ond homozygous patient presented a deletion of exons
4–16 (c.348 + 33_*64 + 146del4285insTA) on both alleles,
and stated having no known inbreeding in her family.
This 4,285 bp deletion was the first LGR to be described
in MUTYH, recently published by us [23] and by an in-
dependent group that found this deletion in a French
patient [33].
For the three patients harboring two distinct pathogenic
variants (ID16, ID18, and ID447), we used allele-specific
PCR to confirm the biallelic nature of the mutations.
All cases presented the hotspot missense mutation
p.Tyr179Cys in one allele accompanied by a second
truncating mutation in the remaining allele (one dele-
tion, one duplication, and one splice site mutation).
One patient (ID24) was a monoallelic carrier of the
hotspot missense mutation p.Gly396Asp, and no other
mutation could be identified.
Clinical features
Clinical records and verbal reports obtained from the 23
index patients and their relatives revealed 113 affected
individuals among all families; their summarized clinical
data are described in Table 2.
Polyposis/CRC age at diagnosis
Across the entire series, the average age at diagnosis and
first symptoms of CRC and/or polyposis was 32.6 years
(range 7–67 years). The mean age of onset in APC-positive
families was 46.3 years (range 35–56) for group 1 (attenu-
ated FAP); 35.7 (range 18–67) for group 2 (intermediateFigure 1 Duplication encompassing exons 1 to 3 of the APC gene (pa
ordered by genomic position; the box marks the probes that indicate dupl
exon numbering [GenBank:NG_008481]). B: Melt curve of duplex qPCR of A
GAPDH peaks of the melting curve was 0.72 in the control sample and 1.06
patient, which confirms the duplication.FAP); and 29.2 (range 7–58) for group 3 (severe FAP).
MAP families presented a mean age of 37.9 years (range
27–53 years); while the average age of onset in families
with no identified mutation was 27.5 years (range 26–29
years). Comparison among the five groups revealed that
the APC-positive group 1, group 2, and MAP patients
demonstrated a later age of onset compared with the se-
vere FAP patients (group 3) (Figure 2).Extracolonic manifestations
Extracolonic manifestations were reported in all APC-
mutated families (Table 2). Gastric and duodenal polyps
(upper gastrointestinal polyps) were the most common
extracolonic manifestations observed in these patients,
and occurred in 11/14 families (79%) and across all
three APC groups. Osteomas were observed most often
in the severe FAP patients (6/9), and epidermoid cysts/
lipomas occurred in the intermediate and severe FAP
patients (5/13).
Desmoid tumors were observed in 8/14 APC-positive
families (57%) and were associated with different muta-
tion sites, with only two of them occurring after codon
1444. Five families had more than one individual af-
fected by desmoid tumors.
MAP families had fewer extracolonic manifestations:
only one family presented upper gastrointestinal polyps
and none presented desmoid tumors.
Regarding other tumor sites, papillary thyroid carcin-
oma appeared in one family of APC group 3; liver and
breast cancers were reported in two families each: one
from group 2 and one from group 3; uterine cancer was
reported in one group 1 and one group 4 (MAP) family.
Finally, lung, hematologic, brain, or skin cancer and mel-
anoma were reported in one family each.tient ID17). A: MLPA graphic showing normalized ratios of probes
ication of APC exons 1, 2, and 3 (exons 4, 5, and 6 according to MLPA
PC exon 2 and GAPDH intron 7 (reference gene). The ratio of APC/
in patient ID17, leading to a normalized ratio of 1.47 for the FAP
Table 2 Clinical features of the 23 Brazilian polyposis families















ID13 1789c attenuated 1 56 56 yes yes no no NA Uterus




ID02 Exon 1–15 del intermediate 5 40-44 42 yes yes no no NA
ID03 1450 intermediate 7 21-54 34.2 yes yes yes (2) no NA Liver; Hematologic
ID04 287 intermediate 14 18-44 29.6 no no no no NA Bilateral breast; Stomach;
BCC
ID05 150 intermediate 18 29-67 40 yes yes yes (3) no yes Breast; Melanoma
3 - Severe FAP APC 7-58 29.2
ID01 302 profuse 5 14-27 23.6 yes no no no NA Brain
ID06 1294 profuse 11 20-35 27.7 yes yes yes (1) yes yes
ID07 283 profuse 8 27-58 37 yes no yes (2) yes yes Liver
ID08 1367 profuse 3 15-55 35 yes yes yes (1) yes NA
ID10 1017 profuse 15 7-55 28.1 no no yes (4) yes yes Thyroid
ID11 1309 profuse 3 30-40 35 yes yes no yes NA
ID14 1465 profuse 8 17-36 26.5 no no yes (2) no yes
ID21 1309 profuse 1 18 18 yes yes no yes no
ID23 1367 profuse 1 22 22 NA NA yes(1) NA NA
4 - MAP MUTYH 27-53 37.9
ID15 Exon 4–16 del attenuated 2 42-44 43 no no no no NA
ID16 179; 385 attenuated 2 30-53 41.5 yes no no no NA Uterus
ID18 130; 179 attenuated 1 45 45 no no no no NA
ID19 241; 241 attenuated 2 27-31 29 no no no no NA
ID24 396;[=] intermediate 1 55 55 NA NA no NA NA
ID447 179; 410 attenuated 2 34-35 34.5 no no no no no
5 - No Mutation 26-29 27.5
ID20 attenuated 1 26 26 no no no yes no
ID22 intermediate 1 29 29 no no no no no
a Polyposis burden of the index case. The remaining columns are based on all affective relatives with available clinical information; b N = number of clinically affected family members; BCC = basal cell carcinoma;



















Figure 2 Age of onset per group. The graph shows the distribution
and the mean (horizontal line) age of onset for each of the five
defined groups. Groups 1, 2, and 4 patients had a significantly later
age of onset than group 3 patients (t = 2.35 p = 0.024; t = 2.15 p = 0.04;
t = 2.01 p = 0.05, respectively).
Figure 3 Genotype–phenotype correlation. A: Distribution of the polypo
along the APC gene. Schematic representation of the two large genomic re
insertions/deletions (circles) identified in this series (including the variant o
denotes patients with desmoid tumors. The lower, thick bar represents the
by Nieuwenhuis and Vasen (2007) [22]. Genotype–phenotype corresponde
concordant colors (blue/green/red/black). Numbers represent APC codons.
according to the index case polyposis phenotype and the APC codon limit
polyposis burden different from that predicted.
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correlations
Genotype–phenotype correlations in polyposis syndromes
have been evaluated in several studies, and a general asso-
ciation between the location of the mutation and the clin-
ical manifestation has been observed, albeit with some
inconsistencies [7,21,34-36]. Recently, Nieuwenhuis and
Vasen (2007) [22] performed a meta-analysis and pro-
posed categorization of the phenotypes into three degrees
of polyposis severity and the associated site of APC muta-
tion. Attenuated FAP was associated with mutations be-
fore codon 157, after codon 1595, and in the alternatively
spliced region of exon 9; severe polyposis was related to
mutations between codons 1250 and 1464; and an inter-
mediate phenotype was associated with APC mutations
located in the remaining sequence of the gene (Figure 3).
We compared the clinical and genetic data from our co-
hort with the APC codon limits defined by Nieuwenhuis
and Vasen (2007) [22]. Figure 3A and B show the distri-
bution of the polyposis phenotype of the index cases
according to the location of their APC mutation, and
compare it with the genotype–phenotype correlations
previously proposed. Nine (64%) of 14 FAP families with
an APC pathogenic mutation presented the expected
polyposis severity according to the location of the APC
mutation, while the remaining five families exhibited
discordant results from the anticipated phenotype. Nine
families presented a profuse polyposis burden (> 1000sis phenotype of the index case and the presence of desmoid tumors
arrangements (top bars) and the 13 point mutations or small
f unknown significance – last circle). The asterisk inside the circles
APC regions defined by genotype–phenotype correlations proposed
nce between our results and those previously published is indicated by
B: Number of families presenting APC point mutations (N = 13)
s, showing that five individuals (underlined numbers) presented a
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two in codon 1367, and one in codon 1294, while the four
remaining patients carried mutations in codons usually
associated with an intermediate number of polyps (codons
283, 302, 1017, and 1465) (Figure 3A and B).
Particular phenotypes
Two of the herein identified mutations presented a
remarkably more aggressive phenotype than expected
given their location and the phenotypes reported in the
literature. The mutation c.447dupC (p.Lys150GlnfsX18),
identified in family ID05, is located in exon 4; the 50 re-
gion of the APC gene is generally associated with attenu-
ated polyposis and later age of onset. While the mean
age of onset in this family (40 years old) was within the
predicted range, the polyposis phenotype caused by this
novel mutation was more aggressive than expected, since
several members of the family presented more than 100
adenomatous polyps. Furthermore, three relatives had
developed a desmoid tumor, usually not observed in pa-
tients with a mutation at the 50 end of the APC gene.
An aggressive phenotypic expression was also observed for
the mutation c.3050–3053delATGA (p.Asn1017MetfsX4),
identified in family ID10 (Figure 4). Although the muta-
tion is located in the region associated with an intermedi-
ate FAP phenotype, the proband presented a high number
of polyps (> 1000) at the age of 15, a desmoid tumor at
the age of 20, and thyroid carcinoma and jaw keratocysts
at 21 years. Her brother and seven cousins also developed
polyps at early ages (7, 14, 15, 19, 17, 22, and two at 29
years old). Desmoid tumors were described in another
three relatives.
Discussion
This is the first report of a comprehensive mutational
analysis and genotype–phenotype correlation in Brazilian
polyposis families. Through direct sequencing of the APC
and MUTYH genes, MLPA, aCGH, and duplex qPCR, we
were able to identify pathogenic mutations in 20 of 23Figure 4 Family tree of ID10 family. This family harbored a truncating m
intermediate FAP phenotype. This mutation displayed an aggressive pheno
presented her first polyposis symptoms at the age of 15, a desmoid tumor
ages of onset are presented under each individual. Her brother (III:2) and si
ages (14 to 29 years old). The most prematurely affected was a second cou
Desmoid tumors were described in another three relatives: two uncles at tindex cases — a detection rate of 87%. Of the remaining
three patients, two were mutation-negative and one har-
bored a novel APC missense variant (p.Val1789Leu). Be-
cause of the lack of affected relatives for co-segregation
analysis and the inconclusive results given by in silico ana-
lysis and control population screening, the clinical sig-
nificance of this alteration is yet to be determined.
Interestingly, a parallel study from our institution, per-
formed in high risk cancer patients, revealed that this pa-
tient also presents a rare germline microdeletion of the
PIP gene possibly associated with an increased cancer risk
(Silva 2013, unpublished observations), suggesting that
these two alterations may be acting in synergy.
The detection rate in polyposis patients from other
populations varies markedly, ranging from 39 to 90%; the
variation reflects different selection criteria for testing and
diverse sensitivity of screening strategies [4,27,37-40].
Our data reinforce the need to apply a combination of
mutation-screening methods to detect the disease-causing
mutation in polyposis patients efficiently. Most APC mu-
tations previously described were identified with conven-
tional methods, for instance denaturing high performance
liquid chromatography or the protein truncation test,
which can have a relatively low detection rate. Nowadays,
the gold standard detection method for polyposis patients
is direct DNA sequencing of all APC and MUTYH coding
exons (including intron–exon boundaries), accompanied
by screening for LGR, as was performed here.
The majority of mutations identified in our cohort were
distinct, except for two families who shared the codon
1309 hotspot APC mutation and three families who
presented the p.Tyr179Cys hotspot mutation in one of
the MUTYH alleles. The absence of the commonly
reported APC mutation at codon 1061, and the relatively
low frequency of the hotspot mutations APC 1309,
MUTYH p.Tyr179Cys, and p.Gly396Asp are consistent
with the fact that Brazilian patients represent an admixed
population, probably lacking a founder APC or MUTYH
mutation.utation at codon 1017 located in a region usually associated with an
typic expression: the proband (individual III:1, indicated by an arrow)
at age 20, and a thyroid carcinoma at age 21. When available, the
x first cousins (III:5, 6, 7, 8, 15, and 22) also developed polyps at early
sin (individual IV:3), who was diagnosed with polyps at the age of 7.
he age of 40 (II:7 and II:9) and one cousin at 32 years old (III:7).
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tions were identified in three families and one family, re-
spectively, and corresponded to 44% of all mutated
alleles identified in this gene (4/9). These are also the
most prevalent mutations in populations of European
origin, probably because of a founder effect, and account
for approximately 80% of all reported mutant alleles
[12]. A recent report described a screen for these two
variants in 30 Brazilian patients with clinical phenotypes
of MAP and FAP; 5/30 patients were identified as carry-
ing one of these two hotspot mutations, and four of
them were in a biallelic state [41]. However, because the
entire coding sequence of MUTYH was not evaluated in
all patients in this study, we cannot perform compari-
sons with the frequency found in our patients.
In our series, we could not identify a causative muta-
tion in two index cases—one with attenuated polyposis
and one with an intermediate polyposis phenotype. A
possible explanation for the polyposis phenotype in these
patients is the presence of unusual mutations in the
APC or MUTYH genes, such as intron or promoter
point mutations, epimutations or genetic mosaicism. In
this sense, a recent study demonstrated that up to 8% of
APC/MUTYH-negative polyposis patients presented a
deep intronic APC variant that led to an aberrant tran-
script [42]. A second possibility is the existence of other
susceptibility genes, and with the current possibility of
screening all coding genes by next generation exome se-
quencing, it can be anticipated that novel polyposis-
predisposing genes will be identified.
Considering that this study is the first comprehensive
analysis of APC and MUTYH mutations in Brazilian
polyposis patients, we attempted to determine the most
cost-effective approach to detect the causative mutation in
this population. In patients presenting fewer than 100
polyps (N = 8), 62% carried a biallelic mutation in the
MUTYH gene. Among patients with more than 100 polyps
(15 cases), three cases presented a mutation in APC exon
8 and eight cases (53%) exhibited a mutation between co-
dons 1017 and 1650 of APC exon 15. Interestingly, this
initial region of exon 15 comprises only 16% of the coding
sequence of APC, yet presented a high mutation rate in
our cohort. Therefore, based on our results, an optimized
scheme for the molecular diagnosis of APC and MUTYH
mutations in the Brazilian population might be obtained
as follows: for patients presenting > 100 polyps, codons
1017–1650 of APC exon 15 should be sequenced first,
followed by exon 8, and then the remaining APC exons;
for patients presenting fewer than 100 polyps, MUTYH
should be firstly screened. Because none of the studied
MUTYH patients presented only the hotspot mutations
p.Tyr179Cys or p.Gly396Asp, the whole gene should be
sequenced, instead of undertaking an initial search for these
variants, as recommended for other populations [18].Genotype–phenotype correlations in polyposis syn-
dromes are of great clinical interest, because they can
contribute to better genetic counseling and simplify mu-
tation screening. In several studies, an association be-
tween the location of the mutation and the clinical
manifestations has been observed [7,20,27,34-36]. How-
ever, since several contradictions have also been reported
[22], it remains unclear whether the genetic information
should guide clinical decision-making, such as the extent
of the prophylactic colectomy or the protocol for clinical
surveillance [7,43-47].
Regarding the age at which clinical surveillance should
begin, the established guidelines suggest that classical
FAP patients should start endoscopic surveillance from
the early teens, while AFAP and MAP families could start
surveillance at age 18–20 [46]. Similar to the literature,
our results demonstrated that severe FAP patients had an
earlier age of onset (on average 10 years younger than
AFAP or MAP patients). However, the most premature
case in our series was a 7-year-old patient from a family
with an APC mutation at codon 1017 — a region usually
associated with an intermediate phenotype. A particularly
aggressive phenotypic expression of this mutation was ob-
served in this family; several relatives presented a high
number of polyps (> 1000), an early age of onset, and des-
moid tumors. This case demonstrates the importance of
considering the family clinical history when planning the
surveillance of other family members.
One of the most clinically important discrepancies ob-
served in our study concerns desmoid tumors, which,
even if histologically benign, can lead to life-threatening
complications through their size and impingement on
vital structures. Indeed, desmoid tumors represent the
second leading cause of death in FAP patients [46,48]
and were identified at high frequency in our cohort, oc-
curring in 57% (8/14) of APC-mutated families. Al-
though described as usually associated with mutations
after codon 1444 [22], only two out of eight families af-
fected by desmoid tumors in our study harbored muta-
tions after this codon. In concordance with our findings,
previous studies with large cohorts have also failed
to confirm this association [49], or described different
boundaries for the increased risk of these tumors, such
as codon 1310 [50] or 1395 [35]. Furthermore, besides
the location of APC mutations, several other risk factors
are suggested to be related with desmoid tumor develop-
ment, such as surgical trauma [51], pregnancy [52] and
especially positive family history for desmoid tumors
[49]. In this regard, the last appears to be the most im-
portant risk factor for our population, since five of eight
families with desmoid tumors presented more than one
relative affected by this tumor.
The differences observed in certain phenotypic fea-
tures between our series and those of others may be
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families, may reflect some selection or data collection
bias, or may be related to phenotypic peculiarities in this
specific population. In this sense, the majority of FAP
genotype-phenotype studies were performed in Europeans
cohorts [34-40,43,47,49] and the self-declared ethnic ori-
gin of most families from our study was also European
(Portuguese, Italian and Spanish, mainly) - except from
two Japanese and one Arabian families. However, it is
important to highlight that Brazilians represent an ex-
tremely admixed population, with most individuals pre-
senting some degree of African and Amerindian ances-
try [53].
Furthermore, intra and interfamilial variations in the
FAP phenotype are also well documented in other popu-
lations, and it is likely that modifying genes and environ-
mental factors, as well as functional polymorphisms of
the normal APC allele, play a crucial role in determining
the clinical course of disease [54,55]. In this regard, the
different genetic background and/or environmental fac-
tors of our population could be responsible for the
phenotypic differences observed in our study. For in-
stance, in our series, desmoid tumors were much more
prevalent in APC-mutated patients (57%) than in others
previous studies (10-15%) [22,49,54], indicating that per-
haps our set of patients represents a distinct group re-
garding this extracolonic feature.
Finally, the lack of a clear phenotypic expression of the
mutations identified in our study complicates clinical
predictions based on knowledge of the mutation site,
and as a result, we can make no specific surveillance and
management recommendations for the Brazilian popula-
tion. In order to accomplish that, larger studies need to
be carried out. Instead, we recommend that clinical deci-
sions regarding an individual patient should not be
based strictly on the genotype, but mainly on the colonic
phenotype and family clinical history.Conclusions
In this comprehensive investigation of the APC and
MUTYH mutation spectrum in Brazilian polyposis pa-
tients, we identified a high frequency of germline mu-
tations, allowing the identification of several novel
pathogenic variants and the proposal of a cost-effective
screening approach for this population. Notably, a sig-
nificant number of APC mutation-positive families were
not consistent with predicted genotype–phenotype cor-
relations, and this should be taken into consideration for
genetic counseling and patient management of our
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